Related Experiment Videos
Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time
Jürgen Weitz1, Christina R Antonescu, Murray F Brennan
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA.
Summary
Survival for extremity soft tissue sarcoma (STS) patients has not improved in 20 years. Known risk factors do not alter this outcome, suggesting current therapies have reached their efficacy limits.
Area of Science:
- Oncology
- Surgical Pathology
- Clinical Outcomes Research
Background:
- Extremity soft tissue sarcomas (STS) are rare malignancies.
- Assessing long-term survival trends is crucial for treatment evaluation.
Purpose of the Study:
- To determine if survival rates for extremity soft tissue sarcoma (STS) patients have improved over the past two decades.
- To analyze survival trends stratified by known prognostic factors.
Main Methods:
- A cohort of 1,261 patients with extremity STS (fibrosarcoma, liposarcoma, leiomyosarcoma, malignant fibrous histiocytoma, or synovial sarcoma) treated between 1982 and 2001 was analyzed.
- Patients underwent complete macroscopic resection.
- Prognostic factors including tumor characteristics, patient demographics, and treatment period were assessed.
Main Results:
- Overall 5-year disease-specific survival remained stable at 79% across different treatment periods (1982-2001).
- For high-risk STS patients, 5-year survival showed no significant improvement, ranging from 45% to 61% across periods.
- Tumor depth, size, grade, margin status, age, recurrence status, and location were significant prognostic factors, but the treatment period was not.
Conclusions:
- The prognosis for extremity soft tissue sarcoma (STS) patients has not improved over the last 20 years.
- Current therapeutic strategies for extremity STS appear to have reached their maximum efficacy.
- Further research into novel treatment modalities is warranted for improving STS patient outcomes.